Dean Diagnosis announced on October 19 that the third quarter of 2026 achieved operating income of 2,635 billion yuan, an increase of 0.23% year on year; net profit to mother of 250 million yuan, an increase of 438.03% year on year; and basic earnings per share of 0.4088 yuan. The first three quarters achieved operating income of 7.409 billion yuan, a year-on-year decrease of 2.07%; net profit to mother of 482 million yuan, an increase of 750.28%; and basic earnings per share of 0.789 yuan. During the reporting period, the company's revenue improved quarterly, and the operating recovery trend was steadily evident; deepened the strategic business layout and continued to increase the revenue share of high-value businesses; continued to expand high-value customers and further increased market share; comprehensively deepened refined management to promote a 1.35 percentage point year-on-year increase in comprehensive gross margin, and the profit structure and profit quality continued to be consolidated.

Dean Diagnosis announced on October 19 that the third quarter of 2026 achieved operating income of 2,635 billion yuan, an increase of 0.23% year on year; net profit to mother of 250 million yuan, an increase of 438.03% year on year; and basic earnings per share of 0.4088 yuan. The first three quarters achieved operating income of 7.409 billion yuan, a year-on-year decrease of 2.07%; net profit to mother of 482 million yuan, an increase of 750.28%; and basic earnings per share of 0.789 yuan. During the reporting period, the company's revenue improved quarterly, and the operating recovery trend was steadily evident; deepened the strategic business layout and continued to increase the revenue share of high-value businesses; continued to expand high-value customers and further increased market share; comprehensively deepened refined management to promote a 1.35 percentage point year-on-year increase in comprehensive gross margin, and the profit structure and profit quality continued to be consolidated.